Salix Pharmaceuticals, Ltd. Release: OSMOPREP™ Tablets Granted MHRA Marketing Approval

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Diacol™ 1500 mg Tablets in the United Kingdom. Diacol, or, sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP, was approved March 16, 2006 by the U.S. FDA and is marketed in the United States under the trade name OsmoPrep™ Tablets.

Back to news